GLPGF - Gilead: Upside From Potential Coronavirus Treatment Could Dissipate
Source: New York Times
Gilead (GILD) is working with regulatory authorities to provide expanded access to remdesivir, which is being offered to coronavirus patients:
Gilead Sciences ((GILD)) has been working with regulatory authorities to start additional expanded access programs for remdesivir, its investigational medicine for COVID-19, Chairman and CEO Daniel O'Day wrote on the company's website.
Such programs allow hospitals or physicians to apply for emergency use of the treatment for multiple severely ill patients at a time.
Even though the medicine isn't yet approved for use by any regulatory authorities, Gilead is